ClinicalTrials.gg
CompletedNCT03521635Updated Feb 16, 2021Results posted

The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa

A Phase 4 interventional study of Pramipexole SR and Pramipexole IR in Parkinson Disease, sponsored by Boehringer Ingelheim. Completed at 12 sites in China. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2021-02-16.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing pramipexole in Parkinson Disease — none open to participants now, none under way, none of them phase 3. Pramipexole · Parkinson Disease.

Enrollment
22nd of 26
98 · median 224
Started
2018
with 1 other
Phase 4
10 of 26
none open now
Registered
24th of 26
by date
Lead sponsor
16 of 26
Boehringer Ingelheim

Among the 26 studies testing pramipexole in Parkinson Disease, this one is the 22nd largest by enrollment, is one of 2 that started in 2018, is one of 10 in phase 4, and was the 24th registered.

Parkinson Disease

4,580 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 26 studies testing pramipexole in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About pramipexole

Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 313 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing pramipexole in Parkinson Disease as a file.
02

Study summary

The main objective of the study is to explore firstly, then further evaluate and confirm the efficacy between Pramipexole Sustained Release (SR) versus Pramipexole Immediate Release (IR) on nocturnal symptoms (as measured by the change from baseline to the end of the maintenance period in Parkinson's Disease Sleep Scale 2nd version (PDSS-2) score) in L-dopa+ treated patients with advanced Parkinson's disease (PD).

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patient with advanced idiopathic Parkinson's disease (PD) confirmed by at least bradykinesia and one of the following signs: resting tremor, rigidity.
  • Diagnosed as Parkinson's disease, with at least 2 years' PD history.
  • Of age ≥ 30 years at time of diagnosis.
  • Modified Hoehn and Yahr stage of 2 to 4 at on-time.
  • They must have sleep disturbances (i.e. Parkinson's Disease Sleep Scale 2nd version (PDSS-2) total score ≥18 at baseline).
  • They must feel uncomfortable at night because they were unable to turn around in bed or move due to immobility (i.e. the scoring of question 9 in PDSS-2 ≥ 2, that means frequency is at least 2 to 3 days during the past week).
  • They must have early morning off (i.e. the frequency of "feeling like bodily movements are poor when you wake up?" is at least 2 to 3 days during the past week).
  • Patient must have motor fluctuations (at least 2 cumulative hours of off-time every day during waking hours, documented on a patient diary completed for 2 consecutive days before randomization visit).
  • Patients must be treated with Levodopa combined with a Dopa-Decarboxylase-inhibitor (L-Dopa+) (i.e. standard and/or controlled release Levodopa/DDC inhibitor), or with a combination of L-Dopa+ and entacapone, at an optimized dose according to investigator's judgment, this dose being stable for at least 4 weeks prior to randomization visit.
  • Patients must not have been treated with sustained release dopaminergic drug (i.e. sustained release Levodopa/Dopa-Decarboxylase (DDC) inhibitor) after supper, or any anti-PD medication after 9pm within 4 weeks prior to randomization visit.
  • Patients must not have been treated with dopamine agonists within 4 weeks prior to randomization visit. A concomitant treatment with one or more of the following drugs will be allowed (at a stable dose for at least 4 weeks prior to randomization visit and the investigator does not intend to change this treatment during the treatment phase):

    • Anti-parkinsonian anticholinergics;
    • Selegiline, rasagiline, or other Monoamine Oxydase (MAO)-B-Inhibitor;
    • Amantadine;
    • Entacapone (or other Catechol-O-Methyltransferase (COMT)-Inhibitor).
  • Male or female patients. Women of (WOCBP) and men able to father a child must be ready and able to use highly effective methods of per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information.
  • Signed and dated written in accordance with ICH-GCP and local legislation prior to admission to the trial.

Exclusion criteria

Exclusion criteria:

  • Secondary parkinsonian syndromes due to drugs (e.g., metoclopramide, flunarizine), metabolic disorders (e.g., Wilson's disease), encephalitis or degenerative diseases (e.g., progressive supranuclear palsy).
  • Dementia, as defined by a score \< 24 at screening visit.
  • Any psychiatric disorder according to Diagnostic and Statistical Manual of Mental Disorders, 5th edition criteria that could prevent compliance or completion of the study and/or put the patient at risk if he/she takes part in the study.
  • History of psychosis, except history of drug induced hallucinations (provided the investigator considers that participation to the trial would not represent a significant risk for the patient).
  • History of deep brain stimulation.
  • History of nucleus lesioning.
  • (ECG) abnormalities at screening visit, according to investigator's judgement.
  • Clinically significant hypotension (i.e. supine systolic blood pressure \< 90 mmHg) and/or symptomatic orthostatic hypotension (i.e. clinical symptoms of orthostatic hypotension associated with a decline ≥ 20 mmHg in systolic blood pressure and a decline ≥ 10 mmHg in diastolic blood pressure, at 1 minute after standing compared with the previous supine systolic and diastolic blood pressure obtained after 5 minutes of quiet rest) at screening or randomization visit.
  • Major surgery (major according to the investigator's assessment) performed within 12 weeks prior to randomization or planned within 12 months after screening, e.g. hip replacement.
  • Any other clinically significant disease, whether treated or not, that could put the patient at risk or could prevent compliance or completion of the study.
  • Serious Sleep Apnea Hypopnea Syndrome (i.e. the scoring of question 15 in Parkinson's Disease Sleep Scale 2nd version (PDSS-2)≥ 3, that means frequency is at least 4 to 5 days during the past week )
  • Any documented active or suspected or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix.
  • Serum levels of (AST)(SGOT), Alanine Aminotransferase (ALT)(SGPT), alkaline phosphatases or total >2 (on screening lab test).
  • Patients with a \< 50 mL/min (estimated by the local lab / the investigator using the Modification of Diet in Renal Disease (, please refer to Appendix 10.1), and calculated on screening lab test).
  • Any hypnotic medication within 4 weeks prior to the randomization visit (i.e. diazepam, clonazepam, estazolam, alprazolam, zolpidem, etc.).
  • Any medication (including intra-muscular formulations) with central dopaminergic antagonist activity within 4 weeks prior to the randomization visit (i.e. typical neuroleptics, atypical antipsychotics, reserpine, methyldopa, centrally-active antiemetics, etc.).
  • Any of the following drugs within 4 weeks prior to randomization visit: methylphenidate, cinnarizine, amphetamines.
  • Flunarizine within 3 months prior to randomization visit.
  • Known to Pramipexole or its .
  • Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
  • Previous enrolment in this trial.
  • Currently enrolled in another device or drug trial, or less than 30 days since ending another investigational device or drug trial(s), or receiving other investigational treatment(s).
  • Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial patient or unlikely to complete the trial.
  • Women who are pregnant, nursing, or who plan to become pregnant in the trial.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    Pramipexole SR

    Drug: Pramipexole SR

  • Active comparator
    Pramipexole IR

    Drug: Pramipexole IR

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 18 in Parkinson's Disease Sleep Scale 2nd Version (PDSS-2) Total Score

    Parkinson's disease Sleep Scale 2nd version (PDSS-2) consists of 15 questions about various sleep and nocturnal disturbances which are to be rated by the patients using one of five categories, from 0 (never) to 4 (very often). Patients were asked to rate the severity of each question based on their experience during the past week (7 days) from 0 (Never) to 4 (Very often, that meant 6 to 7 days a week). PDSS-2 total score ranges from 0 (no disturbance) to 60 (maximum nocturnal disturbance).

    Time frame: Baseline and Week 18

Secondary outcomes

  1. Nocturnal Hypokinesia Questionnaire (NHQ) Score (Change From Baseline)

    The Nocturnal Hypokinesia Questionnaire (NHQ) is designed to assess hypokinesia symptoms in night in Parkinson's disease (PD) patients, composed of two sections. Section 1 is assessed by PD patients with 10 one-point items evaluating "turning over in bed", "getting out of bed", "parkinsonian motor symptoms", and "others". Section 2 is assessed by spouses or caregivers who are with the patients during the night with 10 one-point items evaluating the same aspects as Section 1. The score for each section is by summing up points from the items in the respective section. Score of each of the two Sections is from 0 to 10, with a higher score indicating worse symptoms. The score was reported by section: Section 1 by patients, Section 2 by caregivers.

    Time frame: Baseline and Week 18

  2. Scale for Outcomes in Parkinson's Disease (SCOPA)-Sleep Score (Change From Baseline)

    SCOPA-Sleep score is composed of three parts: a night-time scale (5 item scale with 4 Response Options (0-not at all to 3-very much) addressing night time disturbances. Total night-time scale score runs from 0 to 15, with a higher score indicating more severe problems, a single-item about perceived quality of nocturnal sleep (7-point scale ranging from slept very well to slept very badly.), and a daytime sleepiness scale (6 items with 4 Response options, from 0 (never) to 3 (often), and a maximum total score of 18.).

    Time frame: Baseline and Week 18

  3. Early Morning Off (EMO) Score (Change From Baseline)

    The EMO is measured by the question of "do you feel like your bodily movements are poor when you wake up?" Patients answered this question according to the frequency during the previous one week by scoring from 0 ("never") to 4 ("very often" or "6 to 7 days a week").

    Time frame: Baseline and Week 18

  4. Responder Rate for Parkinson's Disease Sleep Scale 2nd Version (PDSS-2) Total Score<18

    Parkinson's disease Sleep Scale 2nd version (PDSS-2) consists of 15 questions about various sleep and nocturnal disturbances which are to be rated by the patients using one of five categories, from 0 (never) to 4 (very often) based on their experience during the past week. PDSS-2 total score ranges from 0 (no disturbance) to 60 (maximum nocturnal disturbance). The PDSS-2 total score less \< 18 were compared between groups.

    Time frame: At Week 18

  5. Responder Rate for Early Morning Off (EMO) Score

    The responder of EMO is the patient with an improvement of at least 1 comparing to his/her baseline condition. The EMO is measured by the question of "do you feel like your bodily movements are poor when you wake up?" Patients answered this question according to the frequency during the previous one week by scoring from 0 ("never") to 4 ("very often" or "6 to 7 days a week").

    Time frame: At Week 18

  6. The Parkinson's Disease Questionnaire (PDQ)-8 Score (Change From Baseline)

    The PDQ-8 is a self-reported questionnaire consisting of 8 questions regarding the subject's disease symptoms. The total score summed up the items together and transformed onto a score from 0 (never have problems/issues) to 100 (always have problems or cannot do at all).

    Time frame: Baseline and Week 18

  7. Responder Rate for Clinical Global Impression of Improvement (CGI-I)

    The responder of CGI-I is the patient rated of any improvement (1 = Very much better, 2 = Much better, or 3 = A little better). The CGI-I was rated (from 1: very much improved, to 7: very much worse) by the same evaluator to assess the overall status of Parkinson's disease.

    Time frame: At Week 18

  8. Responder Rate for Patient Global Impression of Improvement (PGI-I)

    The responder of PGI-I is the patient rated of any improvement (1 = Very much better, 2 = Much better, or 3 = A little better). The PGI-I scale is a patient-rated instrument (from 1: very much better, to 7: very much worse) which was used to measure the improvement of the patient's Parkinson disease symptoms throughout the study.

    Time frame: At Week 18

  9. Epworth Sleepiness Scale (ESS) Score (Change From Baseline)

    The ESS is a patient-rated scale about how likely one is to fall asleep during situations of passive and inconsequential to active. The total score ranges from 0-24 where higher values indicate greater daytime sleepiness.

    Time frame: Baseline and Week 18

07

Results

Posted Feb 16, 2021
Limitations and caveats
According to the study results, the decision was made to stop transitioning to Stage II. Therefore, only results of Stage I were reported.

Participant flow

This 2-stage open-label, randomised, active controlled parallel group study compared the efficacy and safety of Pramipexole Sustained Release versus Immediate Release administered orally over an 18-week treatment on nocturnal symptoms in patients on Levodopa combined with a Dopa-Decarboxylase-inhibitor with advanced Parkinson's disease.

Participant flow — Overall Study
MilestonePramipexole Sustained ReleasePramipexole Immediate Release
Started4949
Completed4543
Not completed46
Withdrew: Adverse event11
Withdrew: Refused to complete study visit10
Withdrew: Refused to continue trial medication22
Withdrew: Lost to follow-up01
Withdrew: Meet exclusion criteria01
Withdrew: Patient not taken study medicine01

Outcome measures

PrimaryChange From Baseline to Week 18 in Parkinson's Disease Sleep Scale 2nd Version (PDSS-2) Total Score

Parkinson's disease Sleep Scale 2nd version (PDSS-2) consists of 15 questions about various sleep and nocturnal disturbances which are to be rated by the patients using one of five categories, from 0 (never) to 4 (very often). Patients were asked to rate the severity of each question based on their experience during the past week (7 days) from 0 (Never) to 4 (Very often, that meant 6 to 7 days a week). PDSS-2 total score ranges from 0 (no disturbance) to 60 (maximum nocturnal disturbance).

Time frame:
Baseline and Week 18
Reported as:
Mean · Score on a scale
Change From Baseline to Week 18 in Parkinson's Disease Sleep Scale 2nd Version (PDSS-2) Total Score
Score on a scalePramipexole Sustained ReleasePramipexole Immediate Release
Change From Baseline to Week 18 in Parkinson's Disease Sleep Scale 2nd Version (PDSS-2) Total Score-13.7 ± 1.16-14.4 ± 1.20
Statistical analysis
  • Pramipexole Sustained Release vs Pramipexole Immediate Release · REML-based repeated measures approach · p = 0.688 · Adjusted mean difference: 0.7 · 95% CI -2.7 to 4.0Mean difference was calculated as Pramipexole Sustained Release minus Pramipexole immediate Release
SecondaryNocturnal Hypokinesia Questionnaire (NHQ) Score (Change From Baseline)

The Nocturnal Hypokinesia Questionnaire (NHQ) is designed to assess hypokinesia symptoms in night in Parkinson's disease (PD) patients, composed of two sections. Section 1 is assessed by PD patients with 10 one-point items evaluating "turning over in bed", "getting out of bed", "parkinsonian motor symptoms", and "others". Section 2 is assessed by spouses or caregivers who are with the patients during the night with 10 one-point items evaluating the same aspects as Section 1. The score for each section is by summing up points from the items in the respective section. Score of each of the two Sections is from 0 to 10, with a higher score indicating worse symptoms. The score was reported by section: Section 1 by patients, Section 2 by caregivers.

Time frame:
Baseline and Week 18
Reported as:
Mean · Score on a scale
Nocturnal Hypokinesia Questionnaire (NHQ) Score (Change From Baseline)
Score on a scalePramipexole Sustained ReleasePramipexole Immediate Release
By patients (Section 1)-1.9 ± 0.35-1.7 ± 0.36
By caregivers (Section 2)-1.4 ± 0.61-0.6 ± 0.67
Statistical analysis
  • Pramipexole Sustained Release vs Pramipexole Immediate Release · REML-based repeated measures approach · p = 0.690 · Adjusted mean difference: -0.2 · 95% CI -1.2 to 0.8Mean difference was calculated as Pramipexole Sustained Release minus Pramipexole immediate Release.
  • Pramipexole Sustained Release vs Pramipexole Immediate Release · REML-based repeated measures approach · p = 0.376 · Adjusted mean difference: -0.8 · 95% CI -2.7 to 1.1Mean difference was calculated as Pramipexole Sustained Release minus Pramipexole immediate Release.
SecondaryScale for Outcomes in Parkinson's Disease (SCOPA)-Sleep Score (Change From Baseline)

SCOPA-Sleep score is composed of three parts: a night-time scale (5 item scale with 4 Response Options (0-not at all to 3-very much) addressing night time disturbances. Total night-time scale score runs from 0 to 15, with a higher score indicating more severe problems, a single-item about perceived quality of nocturnal sleep (7-point scale ranging from slept very well to slept very badly.), and a daytime sleepiness scale (6 items with 4 Response options, from 0 (never) to 3 (often), and a maximum total score of 18.).

Time frame:
Baseline and Week 18
Reported as:
Mean · Score on a scale
Scale for Outcomes in Parkinson's Disease (SCOPA)-Sleep Score (Change From Baseline)
Score on a scalePramipexole Sustained ReleasePramipexole Immediate Release
Night-time sleep score-3.8 ± 0.46-3.2 ± 0.47
Overall night sleep score-1.9 ± 0.20-1.6 ± 0.21
Daytime sleepiness score-1.4 ± 0.34-0.9 ± 0.35
Statistical analysis
  • Pramipexole Sustained Release vs Pramipexole Immediate Release · REML-based repeated measures approach · p = 0.333 · Adjusted mean difference: -0.6 · 95% CI -1.9 to 0.7Mean difference was calculated as Pramipexole Sustained Release minus Pramipexole immediate Release.
  • Pramipexole Sustained Release vs Pramipexole Immediate Release · REML-based repeated measures approach · p = 0.374 · Adjusted mean difference: -0.3 · 95% CI -0.8 to 0.3Mean difference was calculated as Pramipexole Sustained Release minus Pramipexole immediate Release.
  • Pramipexole Sustained Release vs Pramipexole Immediate Release · REML-based repeated measures approach · p = 0.352 · Adjusted mean difference: -0.5 · 95% CI -1.4 to 0.5Mean difference was calculated as Pramipexole Sustained Release minus Pramipexole immediate Release.
SecondaryEarly Morning Off (EMO) Score (Change From Baseline)

The EMO is measured by the question of "do you feel like your bodily movements are poor when you wake up?" Patients answered this question according to the frequency during the previous one week by scoring from 0 ("never") to 4 ("very often" or "6 to 7 days a week").

Time frame:
Baseline and Week 18
Reported as:
Mean · Score on a scale
Early Morning Off (EMO) Score (Change From Baseline)
Score on a scalePramipexole Sustained ReleasePramipexole Immediate Release
Early Morning Off (EMO) Score (Change From Baseline)-1.8 ± 0.18-1.5 ± 0.18
Statistical analysis
  • Pramipexole Sustained Release vs Pramipexole Immediate Release · REML-based repeated measures approach · p = 0.259 · Adjusted mean difference: -0.3 · 95% CI -0.8 to 0.2Mean difference was calculated as Pramipexole Sustained Release minus Pramipexole immediate Release.
SecondaryResponder Rate for Parkinson's Disease Sleep Scale 2nd Version (PDSS-2) Total Score<18

Parkinson's disease Sleep Scale 2nd version (PDSS-2) consists of 15 questions about various sleep and nocturnal disturbances which are to be rated by the patients using one of five categories, from 0 (never) to 4 (very often) based on their experience during the past week. PDSS-2 total score ranges from 0 (no disturbance) to 60 (maximum nocturnal disturbance). The PDSS-2 total score less \< 18 were compared between groups.

Time frame:
At Week 18
Reported as:
Number · Percentage of participants
Responder Rate for Parkinson's Disease Sleep Scale 2nd Version (PDSS-2) Total Score<18
Percentage of participantsPramipexole Sustained ReleasePramipexole Immediate Release
Responder Rate for Parkinson's Disease Sleep Scale 2nd Version (PDSS-2) Total Score<1873.3 (58.1 to 85.4)72.1 (56.3 to 84.7)
Statistical analysis
  • Pramipexole Sustained Release vs Pramipexole Immediate Release · Regression, Logistic · p = 0.9373 · Odds ratio (or): 0.96 · 95% CI 0.36 to 2.54The odds ratio (OR) between Pramipexole Sustained Release and Pramipexole Immediate Release groups.
SecondaryResponder Rate for Early Morning Off (EMO) Score

The responder of EMO is the patient with an improvement of at least 1 comparing to his/her baseline condition. The EMO is measured by the question of "do you feel like your bodily movements are poor when you wake up?" Patients answered this question according to the frequency during the previous one week by scoring from 0 ("never") to 4 ("very often" or "6 to 7 days a week").

Time frame:
At Week 18
Reported as:
Number · Percentage of participants
Responder Rate for Early Morning Off (EMO) Score
Percentage of participantsPramipexole Sustained ReleasePramipexole Immediate Release
Responder Rate for Early Morning Off (EMO) Score86.7 (73.2 to 94.9)76.7 (61.4 to 88.2)
Statistical analysis
  • Pramipexole Sustained Release vs Pramipexole Immediate Release · Regression, Logistic · p = 0.1611 · Odds ratio (or): 2.24 · 95% CI 0.73 to 7.49The odds ratio (OR) between Pramipexole Sustained Release and Pramipexole Immediate Release groups.
SecondaryThe Parkinson's Disease Questionnaire (PDQ)-8 Score (Change From Baseline)

The PDQ-8 is a self-reported questionnaire consisting of 8 questions regarding the subject's disease symptoms. The total score summed up the items together and transformed onto a score from 0 (never have problems/issues) to 100 (always have problems or cannot do at all).

Time frame:
Baseline and Week 18
Reported as:
Mean · Score on a scale
The Parkinson's Disease Questionnaire (PDQ)-8 Score (Change From Baseline)
Score on a scalePramipexole Sustained ReleasePramipexole Immediate Release
The Parkinson's Disease Questionnaire (PDQ)-8 Score (Change From Baseline)-4.1 ± 0.60-3.5 ± 0.62
Statistical analysis
  • Pramipexole Sustained Release vs Pramipexole Immediate Release · REML-based repeated measures approach · p = 0.517 · Adjusted mean difference: -0.6 · 95% CI -2.3 to 1.2Mean difference was calculated as Pramipexole Sustained Release minus Pramipexole immediate Release.
SecondaryResponder Rate for Clinical Global Impression of Improvement (CGI-I)

The responder of CGI-I is the patient rated of any improvement (1 = Very much better, 2 = Much better, or 3 = A little better). The CGI-I was rated (from 1: very much improved, to 7: very much worse) by the same evaluator to assess the overall status of Parkinson's disease.

Time frame:
At Week 18
Reported as:
Number · Percentage of participants
Responder Rate for Clinical Global Impression of Improvement (CGI-I)
Percentage of participantsPramipexole Sustained ReleasePramipexole Immediate Release
Responder Rate for Clinical Global Impression of Improvement (CGI-I)95.6 (84.9 to 99.5)86.0 (72.1 to 94.7)
Statistical analysis
  • Pramipexole Sustained Release vs Pramipexole Immediate Release · Regression, Logistic · p = 0.2374 · Odds ratio (or): 3.44 · 95% CI 0.57 to 36.85The odds ratio (OR) between Pramipexole Sustained Release and Pramipexole Immediate Release groups.
SecondaryResponder Rate for Patient Global Impression of Improvement (PGI-I)

The responder of PGI-I is the patient rated of any improvement (1 = Very much better, 2 = Much better, or 3 = A little better). The PGI-I scale is a patient-rated instrument (from 1: very much better, to 7: very much worse) which was used to measure the improvement of the patient's Parkinson disease symptoms throughout the study.

Time frame:
At Week 18
Reported as:
Number · Percentage of participants
Responder Rate for Patient Global Impression of Improvement (PGI-I)
Percentage of participantsPramipexole Sustained ReleasePramipexole Immediate Release
Responder Rate for Patient Global Impression of Improvement (PGI-I)95.6 (84.9 to 99.5)86.0 (72.1 to 94.7)
Statistical analysis
  • Pramipexole Sustained Release vs Pramipexole Immediate Release · Regression, Logistic · p = 0.2374 · Odds ratio (or): 3.44 · 95% CI 0.57 to 36.85The odds ratio (OR) between Pramipexole Sustained Release and Pramipexole Immediate Release groups.
SecondaryEpworth Sleepiness Scale (ESS) Score (Change From Baseline)

The ESS is a patient-rated scale about how likely one is to fall asleep during situations of passive and inconsequential to active. The total score ranges from 0-24 where higher values indicate greater daytime sleepiness.

Time frame:
Baseline and Week 18
Reported as:
Mean · Score on a scale
Epworth Sleepiness Scale (ESS) Score (Change From Baseline)
Score on a scalePramipexole Sustained ReleasePramipexole Immediate Release
Epworth Sleepiness Scale (ESS) Score (Change From Baseline)-2.4 ± 0.54-2.6 ± 0.56
Statistical analysis
  • Pramipexole Sustained Release vs Pramipexole Immediate Release · REML-based repeated measures approach · p = 0.820 · Adjusted mean difference: 0.2 · 95% CI -1.4 to 1.7Mean difference was calculated as Pramipexole Sustained Release minus Pramipexole immediate Release.

Adverse events

Collected over From randomisation through end of treatment until end of follow up visit, up to 18 weeks + 2 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pramipexole Sustained Release0/49 (0%)0/49 (0%)4/49 (8.2%)
Pramipexole Immediate Release0/49 (0%)1/49 (2%)7/49 (14.3%)
Most frequent serious events
Most frequent serious events
EventPramipexole Sustained ReleasePramipexole Immediate Release
Mechanical ileusGastrointestinal disorders0/491/49
CholecystitisHepatobiliary disorders0/491/49
CholelithiasisHepatobiliary disorders0/491/49
Femoral neck fractureInjury, poisoning and procedural complications0/491/49
Most frequent other events
Most frequent other events
EventPramipexole Sustained ReleasePramipexole Immediate Release
DizzinessNervous system disorders3/493/49
DyskinesiaNervous system disorders1/493/49
SomnolenceNervous system disorders1/493/49

Baseline characteristics

Treated set (TS) was defined as all patients who were dispensed study medication and were documented to have at least one dose of investigational treatment.

Age, Continuous
Age, Continuous(Years)Pramipexole Sustained ReleasePramipexole Immediate ReleaseTotal
Mean61.1 ± 10.8060.9 ± 8.8361.0 ± 9.82
Sex: Female, Male
Sex: Female, Male(Participants)Pramipexole Sustained ReleasePramipexole Immediate ReleaseTotal
Female211839
Male283159
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pramipexole Sustained ReleasePramipexole Immediate ReleaseTotal
Hispanic or Latino000
Not Hispanic or Latino494998
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pramipexole Sustained ReleasePramipexole Immediate ReleaseTotal
American Indian or Alaska Native000
Asian494998
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Parkinson's disease Sleep Scale 2nd version (PDSS-2) total score
Parkinson's disease Sleep Scale 2nd version (PDSS-2) total score(Score on scale)Pramipexole Sustained ReleasePramipexole Immediate ReleaseTotal
Mean27.8 ± 6.4529.2 ± 8.5328.5 ± 7.56
Parkinson's disease Questionnaire (PDQ) -8 score
Parkinson's disease Questionnaire (PDQ) -8 score(Score on a scale)Pramipexole Sustained ReleasePramipexole Immediate ReleaseTotal
Mean11.3 ± 4.8310.5 ± 4.9910.9 ± 4.90
08

Study locations

12 sites
  • Peking Union Medical College Hospital
    Beijing, 100032, China
  • Beijing Hospital
    Beijing, 100730, China
  • West China Hospital
    Chengdu, 610041, China
  • The First Afiliated Hospital, Sun Yet-sen University
    Guangzhou, 510080, China
  • 2nd Affiliated Hosp Zhejiang University College of Medical
    Hangzhou, 310009, China
  • Brain Hospital Affiliated to Nanjing Med University
    Nanjing, 210029, China
  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, 200025, China
  • The First Hospital of Chinese Medical University
    Shenyang, 110001, China
  • The Second Affiliated Hospital of Soochow University
    Suzhou City, 215004, China
  • Tianjin Medical University General Hospital
    Tianjin, 30052, China
  • Wuhan Union Hospital
    Wuhan, 430022, China
  • First Affiliated Hospital of Xi'an JiaoTong University
    Xian, 710061, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Jan 2020, 18 months.

Results were first posted in Feb 2021, 1 year 1 month after primary completion.

Of 57 phase 4 interventional studies under Parkinson Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 65. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2018
First posted
May 11, 2018
StartActual
Jul 3, 2018
Primary completionActual
Jan 7, 2020
CompletionActual
Jan 7, 2020
Results first posted
Feb 16, 2021
Last update
Feb 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03521635
Responsible party
Sponsor
First posted
May 11, 2018
Start date
Jul 3, 2018
Primary completion
Jan 7, 2020
Completion
Jan 7, 2020
Results posted
Feb 16, 2021
Last update
Feb 16, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion